27 results
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
27 Nov 23
Bankruptcy or Receivership
4:06pm
, or in connection with the Plan and incident to the Chapter 11 Cases, including from the Professional Fee Escrow, has been approved by, or is subject to the approval
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation
8-K
EX-1.1
8bt h4dyplguex90w93
12 Oct 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:46pm
8-K
EX-10.2
l6a5 rtomihs4wy
6 Oct 21
Entry into a Material Definitive Agreement
4:22pm
8-K
EX-1.1
p44yvcayd
8 Sep 21
Other Events
7:10am
8-K
EX-2.1
651iy
30 Jun 21
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
6:04am
8-K
EX-99.1
0guuhq3k
31 Jul 20
Is (I) Not Material and (Ii) Would Likely Cause Competitive Harm to the Company If
4:33pm
8-K
EX-1.1
n83jk6at
15 Jul 20
Other Events
4:52pm
10-K
EX-4.1
5merytf0
28 Mar 19
Annual report
12:00am
S-1/A
EX-4.1
334g3f gguv
1 Oct 18
IPO registration (amended)
12:00am
DRS/A
EX-10.1
ae1zfztj uyb3
13 Jul 18
Draft registration statement (amended)
12:00am
DRS/A
EX-2.2
le8pj7lno9atcwtug8j
13 Jul 18
Draft registration statement (amended)
12:00am